Stay updated on PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial
Sign up to get notified when there's something new on the PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial page.

Latest updates to the PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedAdded a Locations section with Florida as a site, replacing the old Florida Locations label; removed the HHS Vulnerability Disclosure footer link.SummaryDifference0.2%

- Check22 days agoNo Change Detected
- Check43 days agoChange DetectedFooter revision updated: added Revision: v3.3.2 and removed Revision: v3.2.0.SummaryDifference0.1%

- Check51 days agoChange DetectedThe notice about government funding/operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check65 days agoChange DetectedNew navigational links were added under Helpful Links, including 'Moffitt Cancer Center Clinical Trials website' and 'H. Lee Moffitt Cancer Center and Research Institute'. These additions provide quick access to related resources without modifying the study details.SummaryDifference0.6%

- Check93 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference3%

- Check100 days agoChange DetectedThe page update primarily introduces a new version label (v3.1.0) and removes an old term (Melanoma, Cutaneous Malignant) tied to v3.0.2; no substantive core content, pricing, or time-sensitive data appears to be added.SummaryDifference0.3%

Stay in the know with updates to PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial page.